No abstract available.
Graves Disease*

No abstract available.
Graves Disease*

No abstract available.
Graves Ophthalmopathy*

Graves' disease (GD) and Guillain-Barre syndrome (GBS) are both autoimmune disorders and are triggered by interactions between genetic and environmental factors. GBS in patients who suffer from other autoimmune diseases is rarely reported, and the development of atypical GBS with cranial nerve involvement in a patient with GD has never been previously reported. Herein, we report a patient with GD and a rare form of pharyngo-cervico-brachial variety of GBS.

Objective: This study determined the prevalence of Graves ophthalmopathy among thyroid-disease patients at a tertiary government hospital. Methods: Patients with thyroid disease seen at a tertiary hospital from February to September 2007 were enrolled. All patients underwent ophthalmologic examination consisting of visual-acuity testing; exophthalmometry; examination for presence of lid retraction, lid lag, and lateral flare; globe position; external-ocular-muscle-movement grading; corneal light reflex; and direct funduscopic examination. All clinical findings were recorded and data were analyzed. Chi square and Fisher’s exact tests determined the association of gender and age to the different ocular signs and symptoms. One-way analysis of variance (ANOVA) compared the average number of ocular symptoms among the different age groups. Results: A total of 121 patients, 20 males and 101 females, with thyroid disease were evaluated. 47.93% had Graves ophthalmopathy, occurring more frequently among patients aged between 30 and 49 years. The most common signs were eyelid retraction, proptosis, and lid lag. Conclusion Graves ophthalmopathy occurs frequently among patients with thyroid disease, especially those more than 30 years of age.
Graves Ophthalmopathy ; Graves Disease ; Exophthalmos ; Thyroid Diseases

No abstract available.
Diagnosis* ; Graves Disease* ; Korea*

No abstract available.
Genetics* ; Graves Disease*

Studied on 360 patients Basedow in Endocrinology Centre of Hoa Binh province from 1/10/1998-1/10/2000. Results of the study were used by biological statistic with the software SPSS 10.0. Results showed that: Among all samples, 78.89% of patients were effectively treated. All the symptoms (except proptosis) and basic metabolic data were improved. ECG and thyroid ultrasound examination results were also significantly improved. However, the rate of compliance was relatively low. Only 26.11% of patients completed all 3 stages of the clinical trial
Graves Disease ; Therapeutics ; Endocrinology

175 Basedow’s disease patients (45 males and 170 females; mean age: 44.48 ± 8.89) were treated by I-131 at Bach Mai hospital and Military Hospital 103. Total T3 level in serum was 6.45 ± 2.81 nmol/l (n=146) and total T4 level was 243.58 ± 72.34 nmol/l (n=143). Before treatment T3 and T4 level increased abnormaly comparing with healthy people. By 4 months of treatment, T3 level was 2.15 ± 0.78 nmol/l and T4 level was 120.35 ± 36.81nmol/l, FT4 level was 15.67 ± 6.51pmol/l. With average dose of 6.52 ± 1.64 mCi I-131, most of patients had normalized total T3, T4 level
Graves Disease ; Therapeutics

TRAb concentration in the blood of healthy adults and Basedow patients before and after I-131 treatment was measured by RIA (Radioimmunoassay) method. The results were as follow: RIA method for measuring TRAb was standardized. TRAb concentration in the blood of healthy adults was in the very low level (undetectable). TRAb concentrations in the Basedow patients before I-131 treatment were 426.98+/-206.21 mU/ml and by many times higher than that of healthy adults. After I-131 treatment: TRAb concentrations in the 5/12 Basedow patients could not be measured (undetectable) and in 7/12 patients were 127.67+/-59.21 mU/ml.
Graves Disease ; Antibodies ; blood